

Review

Enzymology of NAD⁺ homeostasis in man

G. Magni*, A. Amici, M. Emanuelli, G. Orsomando, N. Raffaelli and S. Ruggieri

Istituto di Biotecnologie Biochimiche, Università Politecnica delle Marche, Via Ranieri 69, 60131 Ancona (Italy),
Fax: +39 0712802117, e-mail: magnig@univpm.it

Received 30 April 2003; received after revision 9 June 2003; accepted 20 June 2003

Abstract. This review describes the enzymes involved in human pyridine nucleotide metabolism starting with a detailed consideration of their major kinetic, molecular and structural properties. The presentation encompasses all the reactions starting from the de novo pyridine ring formation and leading to nicotinamide adenine dinucleotide (NAD⁺) synthesis and utilization. The regulation of NAD⁺ homeostasis with respect to the physiological

role played by the enzymes both utilizing NAD⁺ through the nonredox NAD⁺-dependent reactions and catalyzing the recycling of the common product, nicotinamide, is discussed. The salient features of other enzymes such as NAD⁺ pyrophosphatase, nicotinamide mononucleotide 5'-nucleotidase, nicotinamide riboside kinase and nicotinamide riboside phosphorylase, described under 'miscellaneous', are likewise presented.

Key words. NAD⁺ homeostasis; pyridine nucleotides; structure biology; recombinant enzymes; chromatin expression.

Introduction

Over the past decades, growing evidence accumulated on the paramount importance of the nonredox NAD⁺ functions in the physiology of the cell. NAD⁺ serves as the substrate for reactions involved in important protein covalent modifications, like adenosine 5'-diphosphate (ADP)-ribosylation reactions, catalyzed by two classes of enzymes: mono-ADP-ribosyltransferases (ARTs) and poly(ADP-ribose) polymerases (PARPs) [1]. It has been shown that PARP activation plays a decisive role in NAD⁺ depletion, which is involved in the process of cellular death in many tissues and cells [2]. The maintenance of NAD⁺ levels is also functional to the synthesis of signaling molecules such as cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NaADP⁺). Both metabolites are known to be Ca²⁺ mobilizing agents from intracellular stores acting via distinct mechanisms [3]. An important role of a new member of the PARPs

family, tankyrase, has recently been described [4]. This enzyme, in fact, exerts an indispensable function in the maintenance of genome integrity through the regulation of telomere length homeostasis [5]. About three years ago it was discovered that NAD⁺ is also an essential cofactor in histone/protein deacetylation reactions catalyzed by a new class of enzymes known as the SIR2 family, the products of silent information regulator genes [6]. This discovery suggests that silencing might be related to the metabolic cell rate and hence to NAD⁺ concentrations, whose levels, therefore, seem to be a function directly proportional to a longer life span. The very recent observation that the SIR2 human homologue (SIRT1) acts as an NAD⁺-dependent p53 deacetylase, thus inhibiting p53 cancer-preventing function, raises intriguing questions on the interrelationships governing aging with respect to cancer [7, 8]. The production of reactive oxygen species mediated by the action of free radicals causes irreversible cellular damage, which plays a major role in the pathogenesis of many diseases (e.g., atherosclerosis and neurodegenerative syndromes) generally associated with an altered cellular redox state [9]. The cellular redox state,

* Corresponding author.

also indicated as the cellular redox potential, is related to the ratio of the pyridine dinucleotides in their respective oxidized and reduced forms (NAD⁺/NADH and NADP⁺/NADPH). It is conceivable that an altered regulation of the synthesis and degradation of these metabolites impairs the redox state of the cell and likely contributes to the mechanisms underlying the pathogenesis of the above-mentioned diseases. Even though little time has elapsed since the last comprehensive report on the enzymology of NAD⁺ synthesis was published [10], the amount of data accumulated, ranging from archaea to eubacteria to yeasts to humans, is too large to be reviewed in a single chapter. Therefore, the present report will be devoted to the enzymology of NAD⁺ homeostasis in human.


De novo pyridine ring formation

In case of restricted niacin availability, mammals are able to synthesize nicotinamide-containing nucleotides through the kynurenine pathway (scheme 1), whereby L-tryptophan is metabolized to quinolinate and subsequently to NAD⁺ (scheme 2) [11]. Even though the liver is a major systemic site of the kynurenine pathway [12], the majority of the reports describes the central role played by many metabolites formed along the pathway in the human central nervous system (reviewed in [13–15]).


Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase

In mammals, indoleamine 2,3-dioxygenase (IDO) (EC 1.13.11.17) and tryptophan 2,3-dioxygenase (TDO) (EC

1.13.11.11) catalyze the formation of N-formylkynurenine by cleavage of the pyrrole ring of L-tryptophan and the concomitant insertion of molecular oxygen (scheme 2, reactions 1 and 2). This reaction represents the first rate-limiting step in the tryptophan catabolic pathway. In humans, IDO is ubiquitous in extrahepatic tissues, where it is induced mainly by interferon- γ under a variety of physiological and pathological conditions, including antimicrobial and antitumor defense, immunoregulation and antioxidant activity [16–18]. Furthermore, IDO induction in several viral [19–21], bacterial [22–24] and intracellular protozoan [25] infections, as well as in tumor repression [26, 27], has been widely documented. Its positive role in the defense mechanisms may be related to the enzyme-mediated depletion of tryptophan, the least abundant among essential amino acids, and to the accumulation of its toxic catabolites [28–33]. Recently, many papers appeared on the important role of this enzyme as a modulator of immunological responses: cells expressing IDO are capable of inhibiting T-cell proliferation in vitro, suppressing maternal antifetal immunity during pregnancy and inhibiting T-cell-mediated responses to tumor-associated antigens [34–37]. The IDO-dependent immunoregulation seems to be related to the involvement of tryptophan degradation in T-cell apoptosis [38, 39]. In addition, IDO induction in the brain has been implicated in the pathogenesis of many neurological disorders ascribed to the accumulation of two neurotoxic tryptophan metabolites, quinolinic acid and 3-hydroxykynurenine [40]. Finally, IDO is a unique enzyme in that it can utilize as the substrate, in place of oxygen, the superoxide anion radical ($O_2^{\cdot-}$), thus acting as a radical scavenger. Therefore, its induction during inflammatory conditions has been proposed to prevent oxidative damage to host tissues



Scheme 1. Reaction pathway for quinolinate synthesis. Abbreviations used: IDO, indoleamine 2,3-dioxygenase; TDO, tryptophan 2,3-dioxygenase; KFase, kynurenine formamidase; K3H, kynurenine 3-hydroxylase; Kyase, kynureninase; 3HAO, 3-hydroxyanthranilate 3,4-dioxygenase; N.E., nonenzymatic.



Scheme 2. Panel *A*: Diagrammatic representation of human NAD⁺ metabolism. Panel *B*: List of the enzymatic reactions involved in human NAD⁺ metabolism. The reactions indicated refer to those included in the classification of the ‘Enzyme-Catalyzed Reactions’ recommended by the International Union of Biochemistry and Molecular Biology. Abbreviations used: Kyn, kynurenine; Aa, anthranilic acid; Qa, quinolinic acid; Na, nicotinic acid; Nam, nicotinamide; NmR, nicotinamide riboside; PRPP, 5-phospho- α -D-ribose 1-diphosphate; R-1-P, D-ribose 1-phosphate; NaMN, nicotinate mononucleotide; NaAD⁺, nicotinate adenine dinucleotide; NaADP⁺, nicotinate adenine dinucleotide phosphate.

Scheme 2, panel B

No.	Enzyme designation	EC	Reaction
1	Indoleamine 2,3-dioxygenase	1.13.11.17	Indole + O ₂ ⇌ 2-formylaminobenzaldehyde
2	Tryptophan 2,3-dioxygenase	1.13.11.11	L-Trp + O ₂ ⇌ L-formylkynurenine
3	Kynurenine formamidase	3.5.1.9	N-Formyl-L-kynurenine + H ₂ O ⇌ formate + L-kynurenine
4	Kynurenine 3-hydroxylase	1.14.13.9	L-Kynurenine + NADPH + O ₂ ⇌ 3-hydroxy-L-kynurenine + NADP ⁺ + H ₂ O
5	Kynureninase	3.7.1.3	3-hydroxy-L-Kynurenine + H ₂ O ⇌ 3-hydroxyanthranilate + L-Ala
6	3-Hydroxyanthranilate 3,4-dioxygenase	1.13.11.6	3-Hydroxyanthranilate + O ₂ ⇌ 2-amino-3-carboxymuconate semialdehyde
7	Quinolate phosphoribosyltransferase	2.4.2.19	Quinolate + PRPP ⇌ NMN + PPi + CO ₂
8	NMN adenylyltransferase	2.7.7.1	NMN + ATP ⇌ NAD ⁺ + PPi NaMN + ATP ⇌ NaAD ⁺ + PPi
9	NAD ⁺ synthetase (ammonia-dependent)	6.3.1.5	NaAD ⁺ + ATP + NH ₃ ⇌ NAD ⁺ + AMP + PPi
10	NAD ⁺ synthetase (glutamine-hydrolyzing)	6.3.5.1	NaAD ⁺ + ATP + L-Gln + H ₂ O ⇌ NAD ⁺ + AMP + PPi + L-Glu
11	NAD ⁺ kinase	2.7.1.23	NAD ⁺ + ATP ⇌ NADP ⁺ + ADP
12	NAD ⁺ glycohydrolase	3.2.2.5	NAD ⁺ + H ₂ O ⇌ nicotinamide + ADP-ribose
13	NAD(P) ⁺ nucleosidase	3.2.2.6	NAD(P) ⁺ + H ₂ O ⇌ nicotinamide + ADP-ribose(2'-phosphate)
14	Poly(ADP-ribose) polymerase	2.4.2.30	NAD ⁺ + (ADP-ribose) _n ⇌ nicotinamide + (ADP-ribose) _{n+1}
15	Mono ADPriboseyltransferase	2.4.2.31	NAD ⁺ + L-Arg ⇌ nicotinamide + N(2)-(ADP-ribosyl)-L-Arg
16	NAD ⁺ pyrophosphatase	3.6.1.22	NAD ⁺ + H ₂ O ⇌ AMP + NMN
17	Nicotinamide phosphoribosyltransferase	2.4.2.12	Nicotinamide + PRPP ⇌ NMN + PPi
18	5'-Nucleotidase	3.1.3.5	NMN + H ₂ O ⇌ nicotinamide riboside + Pi
19	Nicotinamide nucleoside phosphorylase	2.4.2.1	Nicotinamide riboside + Pi ⇌ nicotinamide + R-1-P
20	Ribosylnicotinamide kinase	2.7.1.22	ATP + nicotinamide riboside ⇌ ADP + NMN
21	Nicotinamide deamidase	3.5.1.19	Nicotinamide + H ₂ O ⇌ nicotinate + NH ₃
22	Nicotinate phosphoribosyltransferase	2.4.2.11	Nicotinate + PRPP ⇌ NaMN + PPi

[18, 41]. IDO has been purified to homogeneity and characterized from human placenta [30]. The enzyme is a monomeric hemoprotein of about 40,000 M_r , exhibiting a pI value of 6.9. In addition to L-tryptophan, the purified enzyme oxidizes D-tryptophan, 5-hydroxy-L-tryptophan, 5-hydroxy-D-tryptophan and tryptamine, with the K_m value for L-tryptophan (21 μ M) much lower than that found for the other substrates [30]. IDO cDNA has been cloned [42, 43], and the corresponding gene has been mapped to chromosome 8p12-p11 [44, 45]. The pure recombinant protein, expressed in *Escherichia coli* [40, 46], shows the same catalytic properties as the native enzyme [40]. A phylogenetic analysis revealed 25–30% identity of the mammalian IDO with myoglobins of archaeogastropod molluscs, suggesting the existence of a common ancestral gene [47, 48]. Indeed, resonance Raman spectroscopy measurements performed on human IDO heme environment show features common to globins and peroxidases. This analysis suggests a catalytic mechanism whereby a crucial role is played by the strong proximal Fe-His346 bond and the unique distal environment provided by L-tryptophan [49]. The human IDO gene has been fully sequenced and proven to be present in a single copy in the human genome [50]. Its promoter contains interferon-stimulated response element sequences, found in the regulatory region of most interferon-inducible genes [51]. In the mammalian liver, the tryptophan oxidation is catalyzed by the cytosolic enzyme TDO, clearly distinct from IDO. The human TDO gene is localized to chromosome 4q31 [52], and its regulatory region contains a glucocorticoid response-like element [53]. The amino acid sequence of the human enzyme is 88% homologous to that of the rat enzyme [53]. The rat TDO is a tetrameric protein and requires 2 mol of heme per mol of protein for its catalytic function [54]. Different polymorphisms of the human TDO gene have been identified, and the association of these functional variants with psychiatric disorders, characterized by abnormalities in tryptophan and serotonin levels, has been suggested [55, 56].

Kynurenine formamidase

N-Formyl-L-kynurenine is hydrolyzed to L-kynurenine by the action of kynurenine formamidase (KFase) (EC 3.5.1.9) (scheme 2, reaction 3). Surprisingly, to our knowledge no data exist in the literature on the characterization of this enzyme in humans. However, KFase has been isolated and partially characterized from several mammalian sources [10, 57].

Kynurenine 3-hydroxylase

L-Kynurenine is converted to L-3-hydroxykynurenine through a reaction catalyzed by kynurenine 3-hydroxylase (K3H) (EC 1.14.13.9) in the presence of NADPH

and molecular oxygen (scheme 2, reaction 4). The enzyme is a flavin adenine dinucleotide (FAD⁺)-containing monooxygenase localized on the outer membrane of mitochondria. In human tissues, K3H is mostly expressed in the liver and placenta and at lower levels in the kidney [58]. The enzyme is absent in astrocytes and neurons [12, 59], whereas it has been found to be present in microglia [60], blood macrophages [12] and monocyte-derived macrophages, where it can also be induced by bacterial lipopolysaccharides and proinflammatory cytokines [61]. The observation that 3-hydroxykynurenine induces an H₂O₂-mediated neurotoxicity in the central nervous system [62, 63] has stimulated extensive research on this enzyme. Indeed, K3H represents an attractive pharmacological target in that its inhibition both prevents the formation of kynurenic acid, a known neuroprotective metabolite [64], through a divergent route catalyzed by kynurenine aminotransferase [65]. This strongly stimulates the search for novel inhibitors of the enzyme [66]. The human K3H cDNA has been isolated and expressed both in human embryonic kidney fibroblasts (HEK-293) and COS-1 cells [58, 65]. The corresponding gene is localized to chromosome 1q43 [67]. Homogeneous recombinant K3H shows a M_r of about 55,000, a neutral pI value, and it contains one molecule of non-covalently-bound FAD⁺ per molecule of enzyme protein [65]. It shows an optimum pH at 7.5 and uses NADPH more efficiently than NADH [65]. Kinetic measurements reveal a random catalytic mechanism with dissociation constant values for NADPH and kynurenine of 153 μ M and 100 μ M, respectively. Furthermore, inhibition studies indicate that pyridoxal-5'-phosphate (PLP) is a noncompetitive inhibitor with respect to both NADPH and kynurenine substrates, whereas Cl⁻ ions competitively inhibit K3H with respect to NADPH and are noncompetitive inhibitors with respect to kynurenine [65].

Kynureninase

L-3-Hydroxykynurenine is converted to 3-hydroxyanthranilic acid and L-alanine by kynureninase (Kyase) (EC 3.7.1.3) (scheme 2, reaction 5). The enzyme is pyridoxal-5'-phosphate (PLP)-dependent, and its activity is depressed during vitamin B-6 deficiency [68, 69]. Similar to IDO and K3H, human kynureninase is significantly activated by bacterial lipopolysaccharides and proinflammatory cytokines in human monocyte-derived macrophages [61]. The human cDNA codes for a protein of 456 residues, with a M_r of 52,400 [70, 71]. Northern blot analyses performed on different human organs and tissues reveal that the enzyme is ubiquitous, being mostly expressed in the liver, placenta and lung [70]. Analysis of the protein primary structure shows a significant similarity with other eukaryotic enzymes and reveals a PLP-

binding motif typical of the class-V aminotransferases [70, 71]. The protein has been expressed in eukaryotic systems [70–72], and the pure recombinant enzyme possesses a homodimeric structure [72]. The enzyme activity is deeply influenced by the ionic strength and shows an alkaline optimum pH [71, 72]. The homogeneous recombinant enzyme is specific for L-3-hydroxykynurenine, exhibiting a sigmoidal kinetic behavior, with a K_s value of 3 μ M, and it is inhibited by L-kynurenine and D-kynurenine [72]. Finally, it should be mentioned that novel kynurenine analogues potently inhibiting the enzyme have been recently synthesized [72–74].

3-Hydroxyanthranilate 3,4-dioxygenase

The last enzyme-catalyzed reaction in the kynurenine pathway is represented by the conversion of 3-hydroxyanthranilate to α -amino- β -carboxymuconate- ϵ -semialdehyde (ACMS) through the action of 3-hydroxyanthranilate 3,4-dioxygenase (3HAO) (EC 1.13.11.6) (scheme 2, reaction 6). ACMS is a relatively unstable compound undergoing spontaneous cyclization to quinolinic acid. 3HAO is a cytosolic enzyme belonging to the family of intramolecular dioxygenases containing nonheme ferrous iron (Fe^{2+}). The human cDNA, coding for a 286-amino-acid protein, has been cloned and expressed in *E. coli* and human embryonic kidney HEK-293 cells [75, 76]. Kinetic studies performed on purified recombinant 3HAO reveal a K_m value for 3-hydroxyanthranilic acid in the low micromolar range; the enzyme requires the presence of Fe^{2+} for the catalytic activity, whereas it is inhibited by metal cations like Cd^{2+} and Zn^{2+} [75]. Interestingly, the inhibition of 3HAO by Zn^{2+} has been linked to the neurotoxicity caused by an excess of Zn^{2+} ion accumulation [75]. A very recent paper reports on the identification and expression of a cDNA encoding human α -amino- β -carboxymuconate- ϵ -semialdehyde decarboxylase that can divert ACMS to α -amino- β -muconate- ϵ -semialdehyde (AMS), which unlike ACMS, is incapable of forming quinolinate [77]. The fluctuation of this enzyme activity could play a pivotal role in regulating quinolinate concentration and, indirectly, NAD^+ synthesis.

From quinolinate to NAD(P)^+

Quinolinate phosphoribosyltransferase

Quinolinate phosphoribosyltransferase (QaPRT) (EC 2.4.2.19) catalyzes the conversion of quinolinate and 5-phospho- α -D-ribose 1-diphosphate (PRPP) to nicotinate mononucleotide (NaMN), pyrophosphate (PPi) and CO_2 (scheme 2, reaction 7). The enzyme is specific for quinolinate and cannot use either nicotinic acid or nicotinamide as substrates. In addition to the reaction catalyzed by IDO, this reaction represents another rate-limiting step

of the pathway from tryptophan to NAD^+ [78]. In humans, the enzyme has been hypothetically linked to neurological disorders such as epilepsy, Alzheimer disease and Huntington disease because its substrate, quinolinate, is a very well known endogenous excitotoxic agonist of N-methyl-D-aspartate (NMDA) receptors and thereby may modulate the effects of excitotoxins [79–84]. In particular, a substantial reduction in QaPRT activity has been reported in epileptic foci of the human brain [80], while its increase has been described in postmortem brains of Huntington disease victims [82]. Human QaPRT has been purified to homogeneity from both liver and brain tissues, showing identical molecular and kinetic properties [78]. The native protein (M_r 170,000) appears composed of five identical subunits of about 34,000. The K_m values for quinolinate and PRPP are 5.6 μ M and 23 μ M, respectively, and the activity is strictly dependent on the presence of Mg^{2+} ions. Human QaPRT is inhibited by PPi , non competitively with regard to quinolinate and uncompetitively with regard to PRPP [78]. Unfortunately, no data exist on the catalytic mechanism of the reaction catalyzed by the human enzyme, contrary to the detailed kinetic analyses performed on the enzymes from other sources [85–87]. Attempts to isolate quinolinate mononucleotide (QaMN) as the putative reaction intermediate failed because of its spontaneous decarboxylation through the formation of an intermediate nitrogen ylide [88, 89]. The cDNA of human QaPRT has been functionally expressed in *E. coli* [90]. A computer-aided search did not reveal any significant homology with the amino acid sequences of other phosphoribosyltransferases, including both nicotinate and nicotinamide phosphoribosyltransferases, suggesting that the three proteins might not have evolved from a common ancestor. The data obtained confirm the belonging of human QaPRT to the type II phosphoribosyltransferase class [86].

NMN adenylyltransferase

NaMN produced in the reaction catalyzed by QaPRT is linked to the adenosine 5'-monophosphate (AMP) moiety of adenosine 5'-triphosphate (ATP) and converted to nicotinate adenine dinucleotide (NaAD^+) in the reaction catalyzed by NMN adenylyltransferase (NMNAT) (EC 2.7.7.1) (scheme 2, reaction 8). The same enzyme also catalyzes the synthesis of NAD^+ and NaAD^+ utilizing both NMN and NaMN produced in the salvage routes (scheme 2, reactions 16, 17, 20, 22). Since its presence was first demonstrated in yeast [91], NMNAT has been studied for more than 50 years by assuming that it was a single product coded by a single gene [10]. However, in the past six months two new human variants of the enzyme have been identified and characterized [92, 93]. Therefore, the three enzyme forms will be indicated as NMNAT-1, NMNAT-2 and NMNAT-3.

NMNAT-1

The first enzyme purification to homogeneity from human source was achieved more than 10 years ago [94]. Recently, the cDNA encoding NMNAT-1 has been isolated and cloned, and the molecular and kinetic properties of the recombinant human enzyme have been elucidated [95, 96]. The human cDNA codes for a 279-amino-acid protein with a calculated molecular mass of 31,900 Da. Inspection of the primary structure of human NMNAT-1 revealed the presence of a single potential Asn-linked glycosylation site and a putative nuclear localization signal (NLS) [95, 96]. The nuclear localization of the enzyme [96–98] suggested a functional relationship between NMNAT-1 and the chromatin-bound enzyme PARP [99]. Indeed, an inhibitory effect exerted by NMNAT-1 on PARP activity, first observed in this laboratory [100], was later confirmed by others [96]. Therefore, it has been proposed to be an essential role for NMNAT-1 in preventing NAD⁺ and ATP depletion occurring during the cellular rescue from DNA damage caused by PARP over-activation. The possibility that NMNAT-1 expression might also be regulated at the post-translational level has been suggested [96]. Despite its widespread distribution in all organisms, the enzyme is not highly conserved. Human NMNAT-1 lacks the N-terminal extension of about 150 amino acids present in both *Saccharomyces cerevisiae* isoenzymes, and a very low degree of similarity exists with respect to the prokaryotic counterparts [95]. However, human NMNAT-1 shares with all NMNATs so far characterized the conserved ATP-recognition motifs GXFXPT/HXXH and SXTXXR [95, 101]. Like other NMNATs, the human enzyme absolutely requires divalent cations, with optimal activity occurring in the presence of 12 mM Mg²⁺, even though various metal ions can replace magnesium in the reaction mixture [95]. Experimental data seem to indicate a similarity with respect to the cations requirement between human NMNAT-1 and its thermophilic counterpart, whereas yeast isoenzymes exhibit maximal activity with Ni²⁺ and Co²⁺ [102–104]. Initial-rate kinetic studies and product inhibition patterns, obtained analyzing the reaction on both directions [94], showed that the NMNAT-1 catalytic mechanism is ordered Bi-Bi in agreement with the stereochemical data [105]. Compared with the eubacterial enzyme, which appears to prefer NaMN over NMN, human NMNAT-1 seems to use both mononucleotides with the same efficiency, thus being capable of participating in both de novo and salvage pathways of NAD⁺ synthesis [95]. Like other eukaryotic NMNATs [106, 107], NMNAT-1 is able to catalyze the synthesis of NADH from the reduced form of NMN (NMNH), while α -NMN is ineffective both as an inhibitor and as a substrate, suggesting that the nucleotidyl transfer is strongly stereospecific [94]. In addition, NMNAT-1 catalyzes the key step of the metabolic conversion of the antileukemic nucleoside drugs of the

tiazofurin class into NAD⁺ analogues, representing their active form, and loss of NMNAT-1 activity is responsible for drug resistance in resistant leukemic cell lines [108–110]. The human NMNAT-1 gene is localized to chromosome 1p36.2, and its entire structure has been determined [95, 111]. Northern blot analysis reveals a widespread expression in all the examined human tissues, including various parts of the brain, where it is present at a much lower level [95, 111]. Further analysis of NMNAT-1 mRNA expression among a panel of cancer cell lines indicated that, with the exception of Burkitt's lymphoma and chronic myelogenous leukemia, the enzyme is weakly expressed in tumor cells [95]. This result, in agreement with the previously reported data concerning a reduced NMNAT-1 activity after cancerous transformation, makes this enzyme a potential chemotherapeutic target [112–113]. The NMNAT-1 gene has recently been identified as the human homologue of D4Cole1e, the gene that contributes the great majority of amino acids to the chimeric protein that delays Wallerian degeneration in the Wlds mouse [111, 114]. As Wallerian degeneration has a prominent causative role in a spectrum of human neuropathologies, it should be mandatory to evaluate the involvement of the NMNAT-1 gene in neurodegeneration. In this regard, the availability of the entire NMNAT-1 gene structure will allow to screen exons for mutations in neurological disorders as well as to look for single nucleotide polymorphisms [111]. The three-dimensional structure of human recombinant enzyme protein was recently solved through X-ray crystallography, both as apoenzyme (fig. 1) and in different liganded states, thus paving the way to the understanding of its catalytic mechanism at the atomic level as a mandatory step for the rational design of selective and potent inhibitors [101, 115, 116]. The human NMNAT-1 monomer structure contains a central six-stranded parallel β -sheet, flanked by nine α -helices, and connecting loops. A stretch of 37 residues (from 109 to 146) is disordered in the crystal. This region contains the above reported NLS sequence and two serine residues as putative phosphorylation sites (Ser109 and Ser136) that represent a peculiar feature of the human enzyme. The crystal structure shows that human NMNAT-1 forms a barrel-like hexamer, with the NLS- sequence-containing region located at the outer surface of the barrel and therefore able to interact with the nuclear transporting proteins. A cluster of positively charged residues detected at the dimer-dimer interface could be involved in the interaction of human NMNAT-1 with PARP or protein kinases. A comparative analysis of the crystal structures of both complexes of human NMNAT-1 with NAD⁺ and NaAD⁺ [116] allowed clarification of the active site conformation and the structural mechanism underlying the unique dual specificity evolved by the human protein with respect to its prokaryotic counterpart. Further, the structure of human NMNAT-1 com-




Figure 1. Ribbon representation of the hexamer of NMNAT-1 viewed along the local 3-fold axis (A) and the local dyad (B). From Garavaglia et al. [101].

plexed with a noncleavable tiazofurin adenine dinucleotide (TAD) analogue (β -CH₂-TAD) was solved, revealing that the TAD molecule adopts a similar conformation as the native ligand NAD⁺, and that TAD and NAD⁺ form essentially the same interactions with NMNAT-1, except for the extra interactions with the sulfur and nitrogen atoms on the tiazofurin molecule [116]. This finding represents a first step in understanding the molecular mechanisms of the metabolic conversion of nucleoside drugs of the tiazofurin class and producing strategies to prevent or overcome the development of resistance to this oncolytic drug.

NMNAT-2

The human NMNAT-2 isoform, distinct from the nuclear enzyme NMNAT-1, has been recently identified [92, 117]. Its gene has been mapped to chromosome 1q25 [118] and the corresponding cDNA codes for a 307-residue protein, which shares 34 % sequence identity with NMNAT-1. Northern blot analysis performed on RNA from several human tissues and organs revealed that

NMNAT-2 is specifically expressed in the brain [92, 118]. Inspection of the protein primary structure with the PSORT II program suggests a cytoplasmic localization [92]. The presence of this isoform outside the nucleus has been confirmed by localization studies performed with NMNAT-2 tagged with green fluorescent protein (GFP) and overexpressed in cultured cells [93]. These studies demonstrated a highly compartmentalized localization outside the nucleus, which still remains to be exactly determined [93]. Surprisingly, gel filtration experiments on the pure recombinant enzyme expressed in *E. coli* indicated that NMNAT-2 exists as a monomeric protein, whereas the other human isoforms, NMNAT-1 and NMNAT-3, possess an oligomeric structure [92]. Like the nuclear isoform, recombinant NMNAT-2 has a broad pH optimum and performs the adenylyltransferase reaction equally efficiently with both the NMN and NaMN mononucleotides [92, 117]. However, a much lower specific activity, a significantly higher K_m for ATP (870 μ M) and a lower optimal Mg²⁺ concentration (0.3 mM) are exhibited by NMNAT-2 [92]. In addition, the cytoplasmic enzyme contains nine cysteines versus the four cysteines present in NMNAT-1, and it is very prone to oxidation, which can be prevented by thiol protecting agents [92].

NMNAT-3

Very recently, a third isoform of human NMNAT (NMNAT-3) has been identified and structurally characterized [93]. Its cDNA codes for a 252-residue protein that shows 50 % and 34 % identity with NMNAT-1 and NMNAT-2, respectively. The overall mRNA levels in normal tissues are low compared with NMNAT-1. In particular, NMNAT-3 is present in the lung and spleen and, to a lesser extent, in the placenta and kidney [93]. Similarly to NMNAT-1, it is expressed in cancer cell lines at much lower levels [93]. Like NMNAT-2, NMNAT-3 is localized outside the nucleus, but besides being present in the cytosol, it is also present in mitochondria, as demonstrated by the localization experiments on the expressed GFP fusion protein [93]. The enzyme has been overexpressed in *E. coli*, and like the two other isoforms, it shows comparable activity with both NMN and NaMN [93]. The specific activity of NMNAT-3 is lower compared with both NMNAT-1 and NMNAT-2 [93]. The three-dimensional structure of the recombinant protein has been determined in its apo form and in complexes with its substrates or products. The overall structure of the NMNAT-3 monomer, including the active site residues arrangement, is very similar to NMNAT-1; however NMNAT-3 forms a tetramer versus the hexamer of the nuclear isoform [93]. Table 1 summarizes the properties of the human NMNAT isoforms.

NAD⁺ synthetases

NAD⁺ synthetases (EC 6.3.1.5, EC 6.3.5.1) catalyze the formation of NAD⁺ from NaAD⁺ through the amidation

Table 1. Properties of human NMNATs. ^a

Features	NMNAT-1			NMNAT-2			NMNAT-3		
Localization									
– chromosomal	1p32-35			1q25			ND		
– cellular	nuclear			cytosolic			cytosolic/mitochondrial		
Tissue distribution	ubiquitous			brain			ubiquitous		
Northern blot	4.1–3.1 kb			6.6–4.6 kb			1.1 kb		
Structure organization	hexameric			monomeric			tetrameric		
Isoelectric point	9.0			6.6			ND		
Optimal pH	6.0–9.0			6.0–9.0			ND		
Optimal [Mg ²⁺]	12 mM			0.3 mM			ND		
Kinetic parameters	K_m	V_{max}	V_{max}/K_m	K_m	V_{max}	V_{max}/K_m	K_m	V_{max}	V_{max}/K_m
(mM)	(mM)	(U/mg)		(mM)	(U/mg)		(mM)	(U/mg)	
ATP	0.036	51	1417	0.870	15	17.2	ND	ND	ND
NMN	0.023	51	2217	0.091	15	165	ND	4.7	ND
NaMN	0.116	76.5	659	0.125	10.5	84	ND	5.6	ND

ND, not determined.

^a Adapted according to refs. 92, 93 and 95.

of its nicotinic moiety (scheme 2, reactions 9 and 10), the final step in the formation of NAD⁺ both in the de novo synthesis and in the salvage pathways. The NAD⁺-synthetases-catalyzed reaction can use either glutamine or ammonia as the amide group donor and requires stoichiometric hydrolysis of ATP. In a previous review we reported the literature on the existence of different enzymes from several sources utilizing both donors with distinct efficiencies [10]. In eukaryotes, the presence of glutamine-dependent NAD⁺ synthetase activity has long been known in yeast and human erythrocytes [119, 120]. Recently, by using the deduced amino acid sequence of *Bacillus subtilis* NAD⁺ synthetase as a probe in a homology search analysis [121, 122], two different forms of human NAD⁺ synthetases, NADsyn1 and NADsyn2, encoding putative proteins of 706 and 275 amino acids, have been identified and expressed. As determined by SDS-polyacrylamide gel electrophoresis (PAGE), molecular masses of NADsyn1 and NADsyn2 were 80 and 34 kDa, respectively. In nondenaturing conditions, both enzyme forms appear to be oligomeric, consistent with the *B. subtilis* NAD⁺ synthetase topological arrangement [123] and with the proposed two-step mechanism for the reaction [10, 119, 123]. The kinetic characterization showed that the K_m values of NADsyn1 and NADsyn2 for NaAD⁺ and ATP are in the range previously reported for known synthetases [119, 120, 123], whereas the two enzymes differ in the affinities for glutamine and ammonia. The larger form, NADsyn1, shows K_m values of 1.44 mM for glutamine and higher than 10 mM for ammonium ion, while NADsyn2 shows K_m values of over 100 mM for glutamine and 34 μ M for ammonium ion. Therefore, NADsyn1 appears to be a glutamine-dependent NAD⁺ synthetase, while NADsyn2 is a strictly ammonia-dependent NAD⁺ synthetase. This finding shows for the first time the presence of a strictly ammonia-dependent NAD⁺ synthetase in eukaryotes. BLAST alignment of the

NADsyn1 and NADsyn2 amino acid sequences evidenced highly conserved regions in the C-terminal portions comprising the NAD⁺ synthase domain and the P-loop motif, characteristic of the N-type family of ATP-PPases [124]. In addition, the larger NADsyn1 sequence possesses within its N-terminal extension the carbon-nitrogen (CN) hydrolase domain shared by enzymes of the nitrilase family, whose presence is consistent with the ability of NADsyn1 to use glutamine. The CN hydrolase domain is also present in NAD⁺ synthetase from *Mycobacterium tuberculosis* [125, 126], suggesting that glutamine-dependent NAD⁺ synthetases from human and microbes may share a similar mechanism of catalysis and active site structure.

NAD⁺ kinase

NAD⁺ kinase (EC 2.7.1.23) catalyzes the transfer of a phosphate group from ATP to NAD⁺, forming NADP⁺ and ADP (scheme 2, reaction 11). This reaction represents the only known way to generate NADP⁺ in all living organisms. The structural and functional characterization of the human enzyme has been presented only very recently [127]. Based on sequence similarity searches by using the eubacterial enzyme as the query, the human cDNA for NAD⁺ kinase has been identified [127]. The gene is located on chromosome 1p36.21-36.33, and it is expressed in most tissues with the exception of skeletal muscle. The recombinant human enzyme has been expressed in *E. coli* [127]. The pure recombinant protein is composed of four identical subunits of about 49 kDa. Its catalytic activity is optimal at 55 °C and in the pH range of 7.0–8.0. The enzyme requires a divalent cation: Zn²⁺, Mn²⁺ and Mg²⁺ are, in the order, the most effective. Human NAD⁺ kinase is highly selective for the substrates NAD⁺ and ATP, showing K_m values of 0.54 mM and 3.3 mM, respectively. It is not able to phosphorylate NaAD⁺ to NaADP⁺ [127], thus reinforcing the hypothesis that NaADP⁺ synthesis in the cell

exclusively proceeds through the reaction catalyzed by CD38 [128] even though alternative pathways cannot be definitively discounted.

Non redox NAD⁺-dependent reactions

With the name of nonredox NAD⁺-dependent reactions, we indicate those reactions utilizing NAD⁺ and leading to the formation, in addition to nicotinamide, of various metabolites such as ADP-ribose, cADPR, NaADP⁺, O-acetyl-ADP-ribose and poly/mono-ADP-ribosylated proteins (scheme 2, reactions from 12 to 15). In the last few years, excellent reports appeared in the literature reviewing new, exciting data supporting the fundamental role played by these reactions and their products in the most relevant phases of cellular life [129–131]. Therefore, only a brief overview on this topic with specific emphasis on the last published data will be reported. About 30 years ago the demonstration that a large quantity of NAD⁺ synthesis takes place in the nucleus suggested a possible involvement of the pyridine dinucleotide in the modulation of chromatin structure and function [132]. Moreover, NMNAT-1, a key enzyme in NAD⁺ synthesis, was found to be a chromatin-associated protein [133] exhibiting a physical and functional interaction with PARP, another NAD⁺-dependent enzyme [100]. PARP (EC 2.4.2.30) utilizes NAD⁺ by transferring the ADP-ribose moiety to itself as well as to other proteins on specific amino acid residues. The enzyme has been studied and its major kinetic and structural properties characterized in detail for more than 15 years by assuming that it was a single product deriving from a single gene. In the late 1990s, however, it was demonstrated that PARP null mouse cells were able to synthesize ADP-ribose polymers, suggesting the existence of other PARPs [134]. Soon after, indeed, several papers appeared on the existence of multiple genes encoding different forms of the enzyme in animals and humans [135], including tankyrases 1 and 2, PARP-2, V-PARP and PARP-3. Tankyrase-1, a positive regulator of telomere length, possesses a catalytic domain very similar to

PARP-1 but has a different relative mass (142,000) [135, 136]. Tankyrase-2, a second tankyrase with an overall amino acid identity of more than 80% to tankyrase-1, has been identified as a Golgi-associated protein [137]. PARP-2 is a 62-kDa protein very similar to PARP-1, and PARP-3 has not been extensively studied [138]. V-PARP is the 193-kDa protein species of the vault, a ubiquitous ribonucleic particle with unknown function [139]. PARPs belong to a larger family of enzymes that also include those catalyzing mono-ADP-ribosylation reaction, by transferring single ADP-ribose units from NAD⁺ to specific amino acid residues, usually the guanidine group of an arginine or the sulphhydryl group of a cysteine present in target proteins

[140]. In humans, several ARTs (EC 2.4.2.31) have been isolated and functionally and structurally characterized [141]. The results provide good evidence on the involvement of this enzyme activity in the immune response [142]. Another class of enzymes utilizing NAD⁺ is represented by the CD38 family (EC 3.2.2.5, EC 3.2.2.6). CD38 indeed possesses, besides its antigenic function [143], the capability to catalyze different reactions, such as the hydrolysis of NAD⁺ and cADPR to ADP-ribose but also the cyclization of NAD⁺ and nicotinamide guanine dinucleotide (NGD⁺) to cADPR and cyclic GDP-ribose, respectively. Furthermore, it is able to catalyze a base exchange reaction between NADP⁺ and nicotinic acid, thereby producing NaADP⁺ and nicotinamide. Both NaADP⁺ and cADPR act as second messengers, modulating the mobilization of intracellular Ca²⁺ in a large variety of cells including plant, protozoan and human [128]. CD38 is a transmembrane glycoprotein whose cDNA codes for a 30-kDa polypeptide chain. The structure of CD38 has not been determined. However, modeling of the structure of CD38 using the crystallographic data of a functional and structural homologue allowed the identification of a single amino acid residue, Glu146, as the determinant for the NAD⁺ cyclizing and hydrolyzing activities of the protein [144]. It is noteworthy that CD38 has been described to be involved in a model proposed for necrotic beta-cell death. This model implies that the impairment of the CD38-cADPR signal system for insulin secretion is caused by a depletion of NAD⁺ content. Such a depletion is generally secondary to PARP activation because of the occurrence of a cellular insult generating DNA strand breaks [145]. Many reports exist in the literature on the involvement of PARP activity and, consequently, of NAD⁺ levels in multiple cellular processes such as DNA replication, repair and recombination, cell proliferation and death, and gene transcription. The role of NAD⁺ in remodeling chromatin structure and thus in regulating its transcriptional activity through the post-translational modification of chromatin-associated proteins has been dramatically reinforced by the recent discovery that a class of histone/protein deacetylases are NAD⁺-dependent. These enzymes, constituting the SIR2 family, are conserved from prokaryotes to humans [146]. SIR2 proteins, also known as 'sirtuins', catalyze the removal of one acetyl group from the epsilon-amino group of lysine with an accompanying cleavage of one NAD⁺ molecule for each lysine being deacetylated [6, 147, 148]. The products of this reaction are the deacetylated histones/ proteins and a new compound, 2'-O-acetyl-ADP-ribose, which can be further converted to 3'-O-acetyl-ADP-ribose through a nonenzymatic isomerization [149]. The cellular role of these novel compounds is still unclear even though their catalytic formation is evolutionarily conserved among sirtuins, including the human forms [150, 151]. In humans, seven sirtuin genes have been

identified whose cDNAs code for proteins of relative molecular masses ranging from 33,000 to 81,700 [146]. Although a silencing function of human sirtuins can be anticipated by analogy to their *S. cerevisiae* counterparts, little is known about their biological function. However, recent findings demonstrating that human hSIRT1 protein is capable of deacetylating/inactivating p53 [7] and that another human variant, hSIRT3, is localized in mitochondria [152] provide important clues to both their potential substrates and their biological function(s). In addition to poly(ADP-ribose), poly(ADP-ribosylated)-acceptors, deacetylated histones/proteins, cADPR, NaADP⁺, ADPR and O-acetyl-ADP-ribose, all the above-described reactions produce nicotinamide. It is noteworthy that a common distinctive feature of these reactions is the inhibition exerted by nicotinamide toward all the enzymes involved. Therefore, it is conceivable to hypothesize that the fluctuations of nicotinamide concentration regulate the metabolic fluxes occurring in these pathways, which are known to be strictly associated to fundamental events of cellular life. The inhibitory role played by nicotinamide constitutes the basis of the rationale underlying its adoption in therapeutic trials to prevent cancer recurrence and insulin-dependent diabetes [153, 154]. The nicotinamide concentrations in turn fluctuate in response to the activities of the enzymes involved in NAD⁺ recycling. We believe that these studies connecting intermediary metabolism and gene expression will develop into a new and exciting research area with a bright future.

Nicotinamide salvaging

The levels of nicotinamide produced by all the enzymes described in the previous section are intracellularly modulated by the action of three enzymes involved in nicotinamide salvaging, that is, nicotinamide deamidase, nicotinamide phosphoribosyltransferase (NamPRT) and nicotinate phosphoribosyltransferase (NaPRT) (scheme 2, reactions 21, 17 and 22, respectively). Surprisingly, no in-depth studies have been carried out on the characterization of these enzymes in humans despite their evident importance in niacinamide utilization.

Nicotinamide deamidase

Nicotinamide deamidase (EC 3.5.1.19) deamidates nicotinamide substrate to nicotinic acid. Since our previous review on NAD⁺ synthesis [10], no further data are available in the literature on the enzyme from human sources. However, in the same review we did not mention a report showing that in *Plasmodium falciparum*-infected human erythrocytes, a marked nicotinamide deamidase activity can be detected, in contrast to the substantial lack of such activity observed in noninfected human erythro-

cytes. Nevertheless, the authors do not discriminate whether a preexisting, though undetectable, nicotinamide activity is stimulated by the presence of the parasite or encoded by its genome [155].

Nicotinamide phosphoribosyltransferase

NamPRT (EC 2.4.2.12) catalyzes the conversion of nicotinamide and PRPP to NMN and PPi. The presence of this enzymatic activity was first demonstrated in the cytosolic fraction of human erythrocytes [156] and later in human fibroblasts, liver, kidney, lung, brain and spleen [157]; human lymphocytes and lung cancer cell lines [158]; and mitogen-stimulated human T-lymphocytes [159]. Possibly due to the repeatedly reported extreme instability of the enzyme from any source, its purification to homogeneity has never been obtained; thus, the molecular and kinetic characterization of the human enzyme has been sporadic and elusive. The partially purified enzyme from human erythrocytes showed an optimum pH in the range of 6.8–7.6 and an unphysiological K_m value of 100 mM for nicotinamide, suggesting that in humans, this enzyme might not play a significant role in NAD⁺ synthesis [156]. On the other hand, NamPRT from human fibroblasts has been subsequently reported to possess a very low K_m for nicotinamide of 1.6 μ M [157]. More recently, high-pressure liquid chromatography (HPLC)-based determinations also revealed low K_m values for the enzyme from human erythrocytes, corresponding to 12.7 μ M for nicotinamide and 53.7 μ M for PRPP [160, 161]. These low K_m values appear to provide a suitable explanation for the observed active synthesis of NAD⁺ from nicotinamide in intact erythrocytes and NamPRT seems to catalyze the rate-limiting step of this pathway [161, 162]. In contrast to the enzyme from other sources, human NamPRT seems to be stimulated by low ATP concentration and even inhibited by ATP higher than 0.4 mM [162]. Very recently, the product of the murine homologue of the previously identified human pre-B-cell colony-enhancing factor (PBEF) gene [163] has been hypothesized to possess NamPRT enzymatic activity on the basis of its sequence homology to NamPRT from *Haemophilus druceyi* [164]. Indeed, the murine protein, partially purified by immunoprecipitation with anti-PBEF antibody-coupled beads, showed NamPRT activity with a K_m value for nicotinamide of 1.24 μ M, consistent with the values reported for the human fibroblast enzyme [157, 164]. Since the PBEF gene has been reported to be involved in signaling events within the cell, the demonstration that it is endowed with NamPRT activity, though in mouse tissue, suggests that NAD⁺ biosynthesis plays an important role in lymphocyte activation [163, 164]. This finding is consistent with the early reported enhancement of NamPRT activity in mitogen-stimulated human T-lymphocytes [159].

Nicotinate phosphoribosyltransferase

NaPRT (EC 2.4.2.11) catalyzes the conversion of nicotinate and PRPP to NaMN and PP_i. The enzyme-catalyzed formation of NaMN from nicotinate was first described in human erythrocytes [165], and NaPRT was subsequently purified to apparent homogeneity and characterized from the same source [166]. The protein shows a native molecular mass of 86,000 Da. The enzyme activity is optimal over a broad pH range, from pH 6.5 to pH 8.0. Like other mammalian NaPRT enzymes and in contrast with the enzyme from other sources, the activity of human NaPRT is stimulated by ATP, but its requirement is not obligatory. At saturating concentrations, ATP is hydrolyzed to ADP in a 1:1 molar ratio with respect to the formation of NaMN, whereas in the absence of ATP the enzyme is still active, though at a lower rate [166]. In the absence of ATP, K_m values for nicotinate and PRPP are 24 μ M and 100 μ M, respectively, whereas in the presence of saturating ATP, K_m values are 0.5 μ M and 5 μ M, respectively, and the V_{max} value increases by a factor of three. Thus, ATP appears to act both as an energy-yielding cosubstrate and as an enzyme allosteric modulator, and in this respect NaPRT represents a paradigm for a new energy-coupling mechanism of enzyme action [167]. More recently, NaPRT activity has been evaluated in crude extracts from human lymphocytes: the apparent K_m values for nicotinate and PRPP were 0.165 mM and 0.33 mM, respectively [168]. These values, obtained in the absence of added ATP, are much higher than those reported above for the purified erythrocyte enzyme.

Miscellaneous

In this section, the human enzymes involved in the degradation of NAD⁺ by catalyzing reactions leading to the formation of the pyridine mononucleotide, nucleoside and base are described (scheme 2, reactions 16, 18, 19, 20). These routes have been poorly investigated in humans, and, indeed, the literature, refers mainly to sources other than humans [10]. The NAD⁺ formed through the biosynthetic pathways described above can be subjected to the action of NAD⁺ pyrophosphatase (EC 3.6.1.22) (scheme 2, reaction 16). This enzyme activity, catalyzing the cleavage of NAD⁺ to NMN and AMP, has been mostly described in connection with bacterial DNA ligase. Recently, the presence of an activity yielding NMN from NAD⁺ has been described in human blood serum, where its presence was found to be necessary in order to confer virulence to *H. influenzae* [169], thus confirming the early hypothesis on the presence of such an activity in humans [170]. The sera from the same *H. influenzae*-affected patients also contain an NMN phosphohydrolase activity able to cleave NMN to nicotinamide riboside (NMN 5'-nucleotidase, EC 3.1.3.5) (scheme 2, reaction

18), which is involved, together with NAD⁺ pyrophosphatase, in the mechanism underlying the host-mediated virulence of *H. influenzae* [169]. The nicotinamide riboside formed in the reaction catalyzed by NMN 5'-nucleotidase can be reutilized by its conversion to NMN via a reaction catalyzed by human nicotinamide riboside kinase (EC 2.7.1.22) (scheme 2, reaction 20) [171]. The enzyme has been purified to near homogeneity from human placenta by means of a multiple-step purification procedure. The final preparation consists of a monomeric protein whose molecular weight was calculated to be 29,000 under denaturing conditions and 32,000 under native conditions. The pI value is 5.6, and the pH optimum is in the range of 6.5–6.9. The human enzyme exhibits broad substrate specificity, being able to phosphorylate, in addition to nicotinamide riboside, guanosine and, more importantly, tiazofurin and 3-deazaguanosine, known anti-neoplastic agents. The K_m values for these substrates are 9.6 μ M, 115 μ M, 90 μ M and 16.5 μ M, respectively. In addition to its salvaging to NMN, nicotinamide riboside can be cleaved to free nicotinamide by the action of the enzyme nicotinamide riboside phosphorylase (EC 2.4.2.1) (scheme 2, reaction 19). The only existing report on the conversion of nicotinamide riboside to nicotinamide in humans appeared 45 years ago [172]. This old, excellent paper describes several features of the enzyme, partially purified from the soluble fraction of human erythrocytes. The riboside cleavage occurs through a phosphorolytic mechanism, which in principle implies the reversibility of the reaction. Human nicotinamide riboside phosphorylase is subjected to uncompetitive inhibition by nicotinamide. The enzyme pH optimum is 7.5. The enzyme is strictly specific for nicotinamide riboside, being inactive toward other purine, pyrimidine and pyridine nucleosides. Guanosine is the only other riboside utilized as a substrate by the enzyme preparation; it also act as an inhibitor of nicotinamide riboside phosphorolysis.

Conclusions

Our work represents the first overview devoted to the description of human NAD⁺ metabolism, and our aim is to illustrate the state-of-the-art knowledge on the enzymatic routes governing NAD⁺ homeostasis. We hope to draw the attention of researchers who are active in different fields of science, such as biochemistry, pharmacology and experimental medicine, and who are involved in the elucidation of specific physiopathological phenomena where NAD⁺ levels play important functions. In excellent old reviews and also in our comprehensive report, the enzymology of NAD⁺ metabolism occurring in many organisms has been described [10, 173, 174]. Since the last review, many enzymes from human sources have been further molecularly and functionally characterized. How-

ever, detailed structural studies have been carried out only for NMNAT isoforms 1 and 3 and for the enzymes catalyzing the nonredox NAD⁺-dependent reactions like PARPs and CD38. These studies single out these enzymes as druggable targets in a variety of different pathologies including diabetes, inflammatory syndromes, cancer and infectious disease. Furthermore, several enzymes of the pyridine nucleotide metabolism have been shown to perform specific functions within the nervous system. Recently, a therapeutic effect exerted by nicotinamide in brain disease has been suggested [175]. Its potential use as a drug has been expanded and is currently in trials for testing its effectiveness against various diseases [153, 154].

- 1 Ueda K. and Hayaishi O. (1985) ADP-ribosylation. *Annu. Rev. Biochem.* **54**: 73–100
- 2 Germain M., Scovassi I. and Poirier G. G. (2000) Role of poly(ADP-ribose) polymerase in apoptosis. In: *Cell Death: The Role of Poly(ADP-Ribose) Polymerase*, pp. 209–225, Szabo C., CRC Press, Boca Raton, FL
- 3 Clapper D. L., Walseth T. F., Dargle P. J. and Lee H. C. (1987) Pyridine nucleotide metabolites stimulate calcium release from sea urchin egg microsomes desensitized to inositol triphosphate. *J. Biol. Chem.* **262**: 9561–9568
- 4 Smith S., Giriat I., Schmitt A. and de Lange T. (1998) Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. *Science* **282**: 1484–1487
- 5 Griffith J. D., Comeau L., Rosenfield S., Stansel R. M., Bianchi A., Moss H. et al. (1999) Mammalian telomeres end in a large duplex loop. *Cell* **97**: 503–514
- 6 Imai S. I., Armstrong C. M., Kaeberlein M. and Guarente L. (2001) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. *Nature* **403**: 795–800
- 7 Vaziri H., Dessain S. K., Ng Eaton E., Imai S. I., Frye R. A., Pandita T. K. et al. (2001) hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. *Cell* **107**: 149–159
- 8 Luo J., Nikolaev A. Y., Imai S., Chen D., Su F., Shiloh A. et al. (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. *Cell* **107**: 137–148
- 9 Adams J. D., Klaidman L. K., Ghang M. L. and Yang J. (2001) Brain oxidative stress- analytical chemistry and thermodynamics of glutathione and NADPH. *Curr. Top. Med. Chem.* **1**: 473–482
- 10 Magni G., Amici A., Emanuelli M., Raffaelli N. and Ruggieri S. (1999) Enzymology of NAD⁺ synthesis. *Adv. Enzymol. RAMB* **73**: 135–182
- 11 Bender D. A. (1982) Biochemistry of tryptophan in health and disease. *Mol. Aspects Med.* **6**: 101–197
- 12 Heyes M. P., Chen C. Y., Major E. O. and Saito K. (1997) Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. *Biochem. J.* **326**: 351–356
- 13 Schwarcz R. (1993) Metabolism and function of brain kynurenines. *Biochem. Soc. Trans.* **21**: 77–82
- 14 Heyes M. P. (1993) Metabolism and neuropathologic significance of quinolinic acid and kynurenic acid. *Biochem. Soc. Trans.* **21**: 83–89
- 15 Moroni F. (1999) Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. *Eur. J. Pharmacol.* **375**: 87–100
- 16 Carlin J. M., Ozaki Y., Byne G. I., Brown R. R. and Borden E. C. (1989) Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. *Experientia* **45**: 535–541
- 17 Taylor M. W. and Feng G. S. (1991) Relationship between interferon-gamma, indoleamine 2,3-dioxygenase and tryptophan catabolism. *FASEB J.* **5**: 2516–2522
- 18 Thomas S. R. and Stocker R. (1999) Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. *Redox Rep.* **4**: 199–220
- 19 Yoshida R., Urade Y., Tokuda M. and Hayaishi O. (1979) Induction of indoleamine 2,3 dioxygenase in mouse lung during virus infection. *Proc. Natl. Acad. Sci. USA* **76**: 4084–4086
- 20 Heyes M. P., Saito K., Jacobowitz D., Markey S. P., Takikawa O. and Vickers J. H. (1992) Polyovirus induces indoleamine 2,3-dioxygenase and quinolinic acid synthesis in macaque brain. *FASEB J.* **6**: 2977–2989
- 21 Reinhard J. F. Jr (1998) Altered tryptophan metabolism in mice with herpes simplex virus encephalitis: increases in spinal cord quinolinic acid. *Neurochem. Res.* **23**: 661–665
- 22 Yoshida R. and Hayaishi O. (1978) Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. *Proc. Natl. Acad. Sci. USA* **75**: 3998–4000
- 23 Takikawa O., Yoshida R., Kido R. and Hayaishi O. (1986) Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. *J. Biol. Chem.* **258**: 3648–3653
- 24 Daubner W. and MacKenzie C. R. (1999) IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. *Adv. Exp. Med. Biol.* **467**: 517–524
- 25 Sanni L. A., Thomas S. R., Tattam B. N., Moore D. E., Chaudhri G., Stocker R. et al. (1998) Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. *Am. J. Pathol.* **152**: 611–619
- 26 Burke F., Knowles R. G., East N. and Balkwill F. R. (1995) The role of indoleamine 2,3-dioxygenase in the antitumor activity of human interferon gamma in vivo. *Int. J. Cancer* **60**: 115–122
- 27 Dias S., Thomas H. and Balkwill F. R. (1998) Multiple molecular and cellular changes associated with tumor stasis and regression during IL-2 therapy of a murine breast cancer model. *Int. J. Cancer* **75**: 151–157
- 28 Yasui H., Takai K., Yoshida R. and Hayaishi O. (1986) Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3 dioxygenase: its possible occurrence in cancer patients. *Proc. Natl. Acad. Sci. USA* **83**: 6622–6626
- 29 Byrne G. I., Lehmann L. K. and Landry G. J. (1986) Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular *Chlamydia psittaci* replication in T24 cells. *Infect. Immun.* **53**: 347–351
- 30 Takikawa O., Kuroiwa T., Yamazaki F. and Kido R. (1988) Mechanism of interferon-γ action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-γ and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. *J. Biol. Chem.* **263**: 2041–2048
- 31 Ozaki Y., Edelstein M. P. and Duch D. S. (1988) Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon-gamma. *Proc. Natl. Acad. Sci. USA* **85**: 1242–1246
- 32 de la Maza L. M. and Peterson E. M. (1988) Dependence of the in vitro antiproliferative activity of recombinant human gamma-interferon on the concentration of tryptophan in culture media. *Cancer Res.* **48**: 346–350
- 33 Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U. and Ferrara G. B. (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. *J. Exp. Med.* **196**: 459–468

- 34 Munn D. H., Shafizadeh E., Attwood J., Bondarev I., Pashine A. and Mellor A. (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. *J. Exp. Med.* **189**: 1363–1372
- 35 Hwu P., Du M. X., Lapointe R., Do M., Taylor M. W. and Young H. A. (2000) Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. *J. Immunol.* **164**: 3596–3599
- 36 Munn D. H., Zhou M., Attwood J. T., Bondarev I., Conway S. J., Marshall B. et al. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. *Science* **281**: 1191–1193
- 37 Logan G. J., Smith C. M., Earl J. W., Zaikina I., Rowe P. B., Smythe J. A. et al. (2002) HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3 dioxygenase activity. *Immunology* **105**: 478–487
- 38 Fallarino F., Grohmann U., Vacca C., Bianchi R., Orabona C., Spreca A. et al. (2002) T cell apoptosis by tryptophan catabolism. *Cell Death Differ.* **9**: 1069–1077
- 39 Lee G. K., Park H. J., Macleod M., Chandler P., Munn D. H. and Mellor A. L. (2002) Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. *Immunology* **107**: 452–460
- 40 Littlejohn T. K., Takikawa O., Skylas D., Jamie J. F., Walker M. J. and Truscott J. W. (2000) Expression and purification of recombinant human indoleamine 2,3-dioxygenase. *Protein Express. Purif.* **19**: 22–29
- 41 Hayaishi O., Hirata F., Ohnishi T., Henry J. P., Rosenthal I. and Katoh A. (1977) Indoleamine 2,3-dioxygenase incorporation of 18O_2^- and 18O_2 into the reaction products. *J. Biol. Chem.* **252**: 3548
- 42 Dai W. and Gupta S. L. (1990) Molecular cloning, sequencing and expression of human interferon-gamma-inducible indoleamine 2,3-dioxygenase cDNA. *Biochem. Biophys. Res. Commun.* **168**: 1–8
- 43 Tone S., Takikawa O., Habara-Ohkubo A., Kadoya A., Yoshida R. and Kido R. (1990) Primary structure of human indoleamine 2,3-dioxygenase deduced from the nucleotide sequence of its cDNA. *Nucleic Acids Res.* **18**: 367
- 44 Najfeld V., Menninger J., Muhleman D., Comings D. E. and Gupta S. L. (1993) Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12 → p11 by fluorescent in situ hybridization. *Cytogenet. Cell Genet.* **64**: 231–232
- 45 Tone S., Kadoya A., Maeda H., Minatogawa Y. and Kido R. (1994) Assignment of the human indoleamine 2,3-dioxygenase gene to chromosome 8 using the polymerase chain reaction. *Hum. Genet.* **93**: 201–203
- 46 Maeda H., Tone S., Kadoya A., Iwamoto Y., Minatogawa Y. and Kido R. (1992) Expression of human indoleamine 2,3-dioxygenase in *E. coli*. In: *Advances in Tryptophan Research*, pp. 417–420, (Ishiguro I., Kido R., Nagatsu T., Nagamura Y., Otha Y. (eds), Fujita Health University Press, Tokyo
- 47 Suzuki T. and Takagi T. A. (1992) Myoglobin evolved from indoleamine 2,3-dioxygenase. *J. Mol. Biol.* **228**: 698–700
- 48 Suzuki T., Kawamichi H. and Imai K. (1998) Amino acid sequence, spectral, oxygen-binding and autoxidation properties of indoleamine dioxygenase-like myoglobin from the gastropod mollusc *Turbo cornutus*. *J. Protein Chem.* **17**: 817–826
- 49 Terentis A. C., Thomas S. R., Takikawa O., Littlejohn T. K., Truscott R. J. W., Armstrong R. S. et al. (2002) The heme environment of recombinant human indoleamine 2,3-dioxygenase. *J. Biol. Chem.* **277**: 15788–15794
- 50 Kadoya A., Tone S., Maeda H., Minatogawa Y. and Kido R. (1992) Gene structure of human indoleamine 2,3-dioxygenase. *Biochem. Biophys. Res. Commun.* **189**: 530–536
- 51 Konan K. V. and Taylor M. W. (1996) Importance of two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase. *J. Biol. Chem.* **271**: 19140–19145
- 52 Comings D. E., Muhleman D., Dietz G. W. and Donlon T. (1991) Human tryptophan oxygenase localized to 4q31: possible implications for alcoholism and other behavioral disorders. *Genomics* **9**: 301–308
- 53 Comings D. E., Muhlemann D., Dietz G., Sherman M. and Forest G. L. (1995) Sequence of human tryptophan 2,3-dioxygenase (TDO2): presence of a glucocorticoid response-like element composed of a GTT repeat and an intronic CCCCT repeat. *Genomics* **29**: 390–396
- 54 Ren S., Liu H., Licad E., Correia M. A. (1996) Expression of rat liver tryptophan 2,3 dioxygenase in *Escherichia coli*: structural and functional characterization of the purified enzyme. *Arch. Biochem. Biophys.* **333**: 96–102
- 55 Comings D. E., Gade R., Muhleman D., Chiu C., Wu S., To M. et al. (1996) Exon and intron variants in the human 2,3-dioxygenase gene: potential association with Tourette syndrome, substance abuse and other disorders. *Pharmacogenetics* **6**: 307–318
- 56 Vasiliev G. V., Merkulov V. M., Kobzev V. F., Merkulova T. I., Ponomarenko M. P. and Kolchanov N. A. (1999) Point mutations within 663–666 bp of intron 6 of the human TDO2 gene, associated with a number of psychiatric disorders, damage the YY-1 transcription factor binding site. *FEBS Lett.* **462**: 85–88
- 57 Pabarcus M. K. and Casida J. E. (2002) Kynurenine formamidase: determination of primary structure and modeling-based prediction of tertiary structure and catalytic triad. *Biochim. Biophys. Acta* **1596**: 201–211
- 58 Alberati-Giani D., Cesura A. M., Broger C., Warren W. D., Rover S. and Malerbe P. (1997) Cloning and functional expression of human kynurenine 3-monooxygenase. *FEBS Lett.* **410**: 407–412
- 59 Guillemin G. J., Kerr S. J., Smythe G. A., Smith D. G., Kapoor V., Armati P. J. et al. (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. *J. Neurochem.* **78**: 842–853
- 60 Heyes M. P., Achim C. L., Wiley C. A., Major E. O., Saito K. and Markey S. P. (1996) Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. *Biochem J.* **320**: 595–597
- 61 Chiarugi A., Calvani M., Meli E., Traggiai E. and Moroni F. (2001) Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. *J. Neuroimmunol.* **120**: 190–198
- 62 Okuda S., Nishiyama N., Saito H. and Katsuki H. (1996) Hydrogen peroxide-mediated neuronal cell death induced by endogenous neurotoxin, 3-hydroxykynurenine. *Proc. Natl. Acad. Sci. USA* **93**: 12553–12558
- 63 Okuda S., Nishiyama N., Saito H. and Katsuki H. (1998) 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. *J. Neurochem.* **70**: 299–307
- 64 Stone T. W. (1993) Neuropharmacology of quinolinic and kynurenic acids. *Pharmacol. Rev.* **45**: 309–379
- 65 Breton J., Avanzi N., Magagnin S., Covini N., Magistrelli G., Cozzi L. et al. (2000) Functional characterization and mechanism of action of recombinant human kynurenine 3-hydroxylase. *Eur. J. Biochem.* **267**: 1092–1099
- 66 Cozzi A., Carpenedo R. and Moroni F. (1999) Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitro-benzoyl)-alanine (mNBA) and 3,4-dimethoxy-[N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. *J. Cereb. Blood F. Met.* **19**: 771–777
- 67 Halford S., Freedman M. S., Bellingham J., Inglis S. L., Poopalasundar S., Soni B. G. et al. (2001) Characterization of a novel human opsin gene with wide tissue expression and identification of embedded and flanking genes on chromosome 1q43. *Genomics* **72**: 203–208

- 68 van de Kamp J. L. and Smolen A. (1995) Response of kynurenine pathway enzymes to pregnancy and dietary level of vitamin B-6. *Pharmacol. Biochem. Behav.* **51**: 753–758
- 69 Ubbink J. B., Vermaak W. J. and Bissbort S. H. (1991) High-performance liquid chromatographic assay of human lymphocyte kynureninase activity levels. *J. Chromatogr.* **566**: 369–375
- 70 Alberati-Giani D., Buchli R., Malherbe P., Broger C., Lang G., Kohler C. et al. (1996) Isolation and expression of a cDNA clone encoding human kynureninase. *Eur. J. Biochem.* **239**: 460–468
- 71 Toma S., Nakamura M., Toné S., Okuno E., Kido R., Breton J. et al. (1997) Cloning and recombinant expression of rat and human kynureninase. *FEBS Lett.* **408**: 5–10
- 72 Walsh H. A. and Botting N. P. (2002) Purification and biochemical characterization of some of the properties of recombinant human kynureninase. *Eur. J. Biochem.* **269**: 2069–2074
- 73 Fitzgerald D. H., Muirhead K. M. and Botting N. P. (2001) A comparative study on the inhibition of human and bacterial kynureninase by novel bicyclic kynurenine analogues. *Bioorg. Med. Chem.* **9**: 983–989
- 74 Walsh H. A., Leslie P. L., O'Shea K. C. and Botting N. P. (2002) 2-Amino-4-[3'-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. *Bioorg. Med. Chem. Lett.* **12**: 361–363
- 75 Calderone V., Trabucco M., Menin V., Negro A. and Zanotti G. (2002) Cloning of human 3-hydroxyanthranilic acid dioxygenase in *Escherichia coli*: characterization of the purified enzyme and its in vitro inhibition by Zn²⁺. *Biochim. Biophys. Acta* **1596**: 283–292
- 76 Malherbe P., Kohler C., Da Prada M., Lang G., Kiefer V., Schwarcz R. et al. (1994) Molecular cloning and functional expression of human 3-hydroxyanthranilic-acid dioxygenase. *J. Biol. Chem.* **269**: 13792–13797
- 77 Shin-ichi F., Kanako I., Kazumi Y., Atsushi T., Yukari E., Egashira Y. et al. (2002) Identification and expression of a cDNA encoding human α -amino- β -carboxymuconate- ϵ -semialdehyde decarboxylase (ACMSD). *J. Biol. Chem.* **277**: 35162–35167
- 78 Okuno E., White R. J. and Schwarcz R. (1988) Quinolinic acid phosphoribosyltransferase: purification and partial characterization from human liver and brain. *J. Biochem.* **103**: 1054–1059
- 79 Du F., Okuno E., Whetsell W. O. Jr, Kohler C. and Schwarcz R. (1990) Distribution of quinolinic acid phosphoribosyltransferase in the human hippocampal formation and parahippocampal gyrus. *J. Comp. Neurol.* **295**: 71–82
- 80 Feldblum S., Rougier A., Loiseau H., Loiseau P., Cohadon F., Morselli P. L. et al. (1988) Quinolinic-phosphoribosyl transferase activity is decreased in epileptic human brain tissue. *Epilepsia* **29**: 523–529
- 81 Stone T. W. and Perkins M. N. (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. *Eur. J. Pharmacol.* **72**: 411–412
- 82 Foster A. C., Whetsell W. O., Bird E. D. and Schwarcz R. (1985) Quinolinic acid phosphoribosyltransferase in human and rat brain: activity in Huntington disease and in quinolinic-acid-lesioned rat striatum. *Brain Res.* **336**: 207–214
- 83 Heyes M. P., Saito K., Crowley J. S., Davis L. E., Demitrack M. A., Der M. et al. (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurological disease. *Brain* **115**: 1249–1273
- 84 Foster A. C. and Schwarcz R. (1985) Characterization of quinolinic acid phosphoribosyltransferase in human blood and observations in Huntington disease. *J. Neurochem.* **45**: 199–205
- 85 Shibata K. and Iwai K. (1980) Isolation and properties of crystalline quinolinic acid phosphoribosyltransferase from hog kidney. *Biochim. Biophys. Acta* **611**: 280–288
- 86 Cao H., Pietrak B. L. and Grubmeyer C. (2002) Quinolinic acid phosphoribosyltransferase: kinetic mechanism for a type II PRTase. *Biochemistry* **41**: 3520–3528
- 87 Bhatia R. and Calvo K. C. (1996) The sequencing expression, purification and steady-state kinetic analysis of quinolinic acid phosphoribosyl transferase from *Escherichia coli*. *Arch. Biochem. Biophys.* **325**: 270–278
- 88 Eads J. C., Ozturk D., Wexler T. B., Grubmeyer C. and Sacchettini J. C. (1997) A new function for a common fold: the crystal structure of quinolinic acid phosphoribosyltransferase. *Structure* **5**: 47–58
- 89 Kalikin L. and Calvo K. C. (1988) Inhibition of quinolinic acid phosphoribosyl transferase by pyridine analogs of quinolinic acid. *Biochem. Biophys. Res. Commun.* **152**: 559–564
- 90 Fukuoka S. I., Nyaruhucha C. M. and Shibata K. (1998) Characterization and functional expression of the cDNA encoding human brain quinolinic acid phosphoribosyltransferase. *Biochim. Biophys. Acta* **1395**: 192–201
- 91 Kornberg A. (1948) The participation of inorganic pyrophosphate in the reversible enzymatic synthesis of diphosphopyridine nucleotide. *J. Biol. Chem.* **176**: 1475–1476
- 92 Raffaelli N., Sorci L., Amici A., Emanuelli M., Mazzola F. and Magni G. (2002) Identification of a novel human nicotinamide mononucleotide adenylyltransferase. *Biochem. Biophys. Res. Commun.* **297**: 835–840
- 93 Zhang X., Kurnasov O. V., Karthikeyan S., Grishin N. V., Osterman A. L. and Zhang H. (2003) Structural characterization of a human cytosolic NMN/NaMN adenylyltransferase and implication in human NAD biosynthesis. *J. Biol. Chem.* **278**: 13503–13511
- 94 Emanuelli M., Natalini P., Raffaelli N., Ruggieri S., Vita A. and Magni G. (1992) NAD biosynthesis in human placenta: purification and characterization of homogeneous NMN adenylyltransferase. *Arch. Biochem. Biophys.* **298**: 29–34
- 95 Emanuelli M., Carnevali F., Saccucci F., Pierella F., Amici A., Raffaelli N. et al. (2001) Molecular cloning, chromosomal localization, tissue mRNA levels, bacterial expression and enzymatic properties of human NMN adenylyltransferase. *J. Biol. Chem.* **276**: 406–412
- 96 Schweiger M., Hennig K., Lerner F., Niere M., Hirsch-Kauffmann M., Specht T. et al. (2001) Characterization of recombinant human nicotinamide mononucleotide adenylyl transferase (NMNAT), a nuclear enzyme essential for NAD synthesis. *FEBS Lett.* **492**: 95–100
- 97 Ruggieri S. and Magni G. (1982) Isolation of yeast nuclei. Evidence of chromatin-associated proteolytic activity. *Physiol. Chem. Phys.* **14**: 315–321
- 98 Balducci E., Emanuelli M., Magni G., Raffaelli N., Ruggieri S., Vita A. et al. (1992) Nuclear matrix-associated NMN adenylyltransferase activity in human placenta. *Biochem. Biophys. Res. Commun.* **189**: 1275–1279
- 99 Uhr M. L. and Smulson M. (1982) NMN adenylyltransferase: its association with chromatin and with poly(ADP-ribose) polymerase. *Eur. J. Biochem.* **128**: 435–443
- 100 Ruggieri S., Gregori L., Natalini P., Vita A., Emanuelli M., Raffaelli N. et al. (1990) Evidence for an inhibitory effect exerted by yeast NMN adenylyltransferase on poly(ADP-ribose)polymerase activity. *Biochemistry* **29**: 2501–2506
- 101 Garavaglia S., D'Angelo I., Emanuelli M., Carnevali F., Pierella F., Magni G. et al. (2002) Structure of human NMN adenylyltransferase. A key nuclear enzyme for NAD homeostasis. *J. Biol. Chem.* **277**: 8524–8530
- 102 Raffaelli N., Pisani F. M., Lorenzi T., Emanuelli M., Amici A., Ruggieri S. et al. (1997) Characterization of nicotinamide mononucleotide adenylyltransferase from thermophilic archaea. *J. Bacteriol.* **179**: 7718–7723
- 103 Emanuelli M., Carnevali F., Lorenzi M., Raffaelli N., Amici A., Ruggieri S. et al. (1999) Identification and characterization of YLR328W, the *Saccharomyces cerevisiae* structural

- gene encoding NMN adenylyltransferase. Expression and characterization of the recombinant enzyme. *FEBS Lett.* **445**: 13–17
- 104 Emanuelli M., Amici A., Carnevali F., Pierella F., Raffaelli N. and Magni G. (2003) Identification and characterization of a second NMN adenylyltransferase gene in *Saccharomyces cerevisiae*. *Protein Expr. Purif.* **27**: 357–364
 - 105 Lowe G. and Tansley G. (1983) The stereochemical course of nucleotidyl transfer catalyzed by NAD pyrophosphorylase. *Eur. J. Biochem.* **132**: 117–120
 - 106 Kornberg A. (1950) Reversible enzymatic synthesis of diphosphopyridine nucleotide and inorganic pyrophosphate. *J. Biol. Chem.* **182**: 779–793
 - 107 Balducci E., Orsomando G., Polzonetti V., Vita A., Emanuelli M., Raffaelli N. et al. (1995) NMN adenylyltransferase from bull testis: purification and properties. *Biochem. J.* **310**: 395–400
 - 108 Jayaram H. N., Pillwein K., Lui M. S., Faderan M. A. and Weber G. (1986) Mechanism of resistance to tiazofurin in hepatoma 3924A. *Biochem. Pharmacol.* **35**: 587–593
 - 109 Boulton S., Kyle S. and Durkacz B. W. (1997) Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair. *Br. J. Cancer.* **76**: 845–851
 - 110 Jager W., Salamon A. and Szekeres T. (2002) Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside. *Curr. Med. Chem.* **9**: 781–786
 - 111 Shama Fernando F., Conforti L., Tosi S., Smith A. D. and Coleman M. P. (2002) Human homologue of a gene mutated in the slow Wallerian degeneration (C57BL/Wlds) mouse. *Gene* **284**: 23–29
 - 112 Morton R. K. (1958) Enzymic synthesis of coenzyme I in relation to chemical control of cell growth. *Nature* **181**: 540–542
 - 113 Emanuelli M., Raffaelli N., Amici A., Balducci E., Natalini P., Ruggieri S. et al. (1995) The antitumor drug, 1,3-bis(2-chloroethyl)-1-nitroso-urea, inactivates human nicotinamide mononucleotide adenylyltransferase. *Biochem. Pharmacol.* **49**: 575–579
 - 114 Mack T. G., Reiner M., Beirowski B., Mi W., Emanuelli M., Wagner D. et al. (2001) Wallerian degeneration of injured axons and synapses is delayed by Ube4b/Nmnat chimeric gene. *Nat. Neurosci.* **4**: 1199–206
 - 115 Werner E., Ziegler M., Lerner F., Schweiger M. and Heine-mann U. (2002) Crystal structure of human nicotinamide mononucleotide adenylyltransferase in complex with NMN. *FEBS Lett.* **516**: 239–244
 - 116 Zhou T., Kurnasov O., Tomchick D. R., Binns D. D., Grishin N. V., Marquez V. E. et al. (2002) Structure of human nicotinamide/nicotinic acid mononucleotide adenylyltransferase. Basis for the dual substrate specificity and activation of the oncolytic agent tiazofurin. *J. Biol. Chem.* **277**: 13148–13154
 - 117 Gerdes S. Y., Scholle M. D., D'Souza M., Bernal A., Baev M. V., Farrel M. et al. (2002) From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. *J. Bacteriol.* **184**: 4555–4572
 - 118 Sood R., Bonner T. I., Makalowska I., Stephan D. A., Robbins C. M., Connors T. D. et al. (2001) Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus. *Genomics* **73**: 211–222
 - 119 Yu C. K. and Dietrich L. S. (1972) Purification and properties of yeast nicotinamide adenine dinucleotide synthetase. *J. Biol. Chem.* **247**: 4794–4802
 - 120 Zerez C. R., Wong M. D. and Tanaka K. R. (1990) Partial purification and properties of nicotinamide adenine dinucleotide synthetase from human erythrocytes: evidence that enzyme activity is a sensitive indicator of lead exposure. *Blood* **75**: 1576–1582
 - 121 Nessi C., Albertini A. M., Speranza M. L. and Galizzi A. (1995) The outB gene of *Bacillus subtilis* codes for NAD synthetase. *J. Biol. Chem.* **270**: 6181–6185
 - 122 Hara N., Yamada K., Terashima M., Osago H., Shimoyama M. and Tsuchiya M. (2003) Molecular identification of human glutamine- and ammonia-dependent NAD synthetases. *J. Biol. Chem.* **278**: 10914–10921
 - 123 Rizzi M., Nessi C., Mattevi A., Coda A., Bolognesi M. and Galizzi A. (1996) Crystal structure of NH₃-dependent NAD⁺ synthetase from *Bacillus subtilis*. *EMBO J.* **15**: 5125–5134
 - 124 Tesmer J. G., Klem T. J., Deras M. L., Davisson, V. J. and Smith J. (1996) The crystal structure of GMP synthetase reveals a novel catalytic triad and is a structural paradigm for two enzyme families. *Nat. Struct. Biol.* **3**: 74–86
 - 125 Cantoni R., Branzoni M., Labò M., Rizzi M. and Riccardi G. (1998) The MTCY428.08 gene of *Mycobacterium tuberculosis* codes for NAD⁺ synthetase. *J. Bacteriol.* **180**: 3218–3221
 - 126 Bellinzoni M., De Rossi E., Branzoni M., Milano A., Peverali F. A., Rizzi M. and Riccardi G. (2002) Heterologous expression, purification and enzymatic activity of *Mycobacterium tuberculosis* NAD synthetase. *Protein Expr. Purif.* **25**: 547–557
 - 127 Lerner F., Niere M., Ludwig A. and Ziegler M. (2001) Structural and functional characterization of human NAD kinase. *Biochem. Biophys. Res. Commun.* **288**: 69–74
 - 128 Lee H. C. (2002) *Cyclic ADP-Ribose and NAADP-Structure Metabolism and Function*, Kluwer Academic Publisher, Boston
 - 129 Smith S. (2001) The world according to PARP. *Trends Biochem. Sci.* **26**: 174–179
 - 130 Lee H. C. (2001) Physiological function of cyclic ADP-ribose and NAADP as calcium messengers. *Annu. Rev. Pharmacol. Toxicol.* **41**: 317–345
 - 131 Denu J. M. (2003) Linking chromatin function with metabolic networks: Sir2 family of NAD⁺-dependent deacetylases. *Trends Biochem. Sci.* **28**: 41–48
 - 132 Rechsteiner M. and Catanzarite V. (1974) Biosynthesis and turnover of nicotinamide adenine dinucleotide in enucleated culture cells. *J. Cell Physiol.* **84**: 409–422
 - 133 Magni G., Raffaelli N., Emanuelli M., Amici A., Natalini P. and Ruggieri S. (1997) Nicotinamide-monomononucleotide adenylyltransferases from yeast and other microorganisms. *Methods Enzymol.* **280**: 248–254
 - 134 Shieh M., Amé J. C., Wilson M. W., Wang Z. K., Koh D. W., Jacobson M. K. et al. (1998) Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. *J. Biol. Chem.* **273**: 30069–30072
 - 135 Smith S. and de Lange T. (2000) Tankyrase, promotes telomere elongation in human cells. *Curr. Biol.* **10**: 1299–1302
 - 136 Rippmann J. F., Damm K. and Schnapp A. (2002) Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length. *J. Mol. Biol.* **323**: 217–224
 - 137 Lyons R. J., Deane R., Lynch D. K., Ye Z. S., Sanderson G. and Eyre H. J. (2001) Identification of a novel human tankyrase through its interaction with the adaptor protein Grb14. *J. Biol. Chem.* **276**: 17172–17180
 - 138 Johansson M. (1999) A human poly(ADP-ribose) polymerase gene family (ADPRTL): cDNA cloning of two novel poly(ADP-ribose) polymerase homologues. *Genomics* **57**: 442–445
 - 139 Kichhoefer V. A., Siva A. C., Kedersha N. L., Inman E. M., Ruland C., Streuli M. et al. (1999) The 193-kD vault protein is a novel poly(ADP-ribose) polymerase. *J. Cell Biol.* **146**: 917–928
 - 140 Okazaki I. J. and Moss J. (1996) Structure and function of eukaryotic mono-ADP-ribosyltransferases. In: *Reviews of Physiology, Biochemistry and Pharmacology*, pp. 51–103, Blauenstein M. P. and Grunicke H. (eds), Springer-Verlag, New York

- 141 Han S. and Tainer J. A. (2002) The ARTT motif and a unified structural understanding of substrate recognition in ADP-ribosylating bacterial toxins and eukaryotic ADP-ribosyltransferases. *Int. J. Med. Microbiol.* **291**: 523–529
- 142 Grahnert A., Friedrich M., Pfister M., Haag F., Koch-Nolte F. and Hauschildt S. (2002) Mono-ADP-ribosyltransferases in human monocytes: regulation by lipopolysaccharide. *Biochem. J.* **362**: 717–723
- 143 Malavasi F., Funaro A., Roggero S., Horenstein A., Colosso L. and Mehta K. (1994) Human CD38: a glycoprotein in search of a function. *Immunol. Today* **15**: 95–97
- 144 Graeff R., Munshi C., Aarhus R., Johns M. and Lee H. C. (2001) A single residue at the active site of CD38 determines its NAD cyclizing and hydrolyzing activities. *J. Biol. Chem.* **276**: 12169–12173
- 145 Okamoto H. and Takasawa S. (2002) The CD38-cyclic ADP-ribose signal system and the regenerating gene protein (Reg)-Reg receptor system in beta-cells. *Diabetes* **51**: S462–S473
- 146 Frye R. A. (2000) Phylogenetic classification of prokaryotic and eukaryotic SIR2-like proteins. *Biochem. Biophys. Res. Commun.* **273**: 793–798
- 147 Tanner K. G., Landry J., Sternglanz R. and Denu J. M. (2000) Silent information regulator 2 family of NAD⁺-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. *Proc. Natl. Acad. Sci. USA* **97**: 14178–14182
- 148 Tanny J. C. and Moazed D. (2001) Coupling of histone deacetylation to NAD⁺ breakdown by the yeast silencing protein SIR2: evidence for acetyl transfer from substrate to an NAD⁺ breakdown product. *Proc. Natl. Acad. Sci. USA* **98**: 415–420
- 149 Sauve A. A., Celic I., Avalos J., Deng H., Boeke J. D. and Schramm V. L. (2001) Chemistry of gene silencing: the mechanism of NAD⁺-dependent deacetylation reactions. *Biochemistry* **40**: 15456–15463
- 150 Jackson D. M. and Denu J. M. (2002) Structural identification of 2'-an3'-O-acetyl-ADP-ribose as novel metabolites derived from the SIR2 family of beta-NAD⁺-dependent histone/protein deacetylases. *J. Biol. Chem.* **277**: 18535–18544
- 151 Borra M. T., O'Neil F. J., Jackson M. D., Marshall. B., Verdin E., Foltz K. R. et al. (2002) Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD⁺-dependent deacetylases. *J. Biol. Chem.* **277**: 12632–12641
- 152 Schwer B., North B. J., Frye R. A., Ott M. and Verdin E. (2002) The human silent information regulator (Sir)2 homologue is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. *J. Cell Biol.* **158**: 647–657
- 153 Gale E. A. (2003) Intervening before the onset of type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). *Diabetologia* **46**: 339–346
- 154 Kaanders J. H., Bussink J. and Van der Kogel A. J. (2002) A novel biology-based approach in radiotherapy. *Lancet Oncol.* **3**: 728–737
- 155 Zerez C. R., Roth E. F. Jr, Schulman S. and Tanaka K. R. (1990) Increased nicotinamide adenine dinucleotide content and synthesis in *Plasmodium falciparum*-infected human erythrocytes. *Blood* **75**: 1705–1710
- 156 Preiss J. and Handler P. (1957) Enzymatic synthesis of nicotinamide mononucleotide. *J. Biol. Chem.* **225**: 759–770
- 157 Elliott G. C., Ajioka J. and Okada C.Y. (1980) A rapid procedure for assaying nicotinamide phosphoribosyltransferase. *Anal. Biochem.* **107**: 199–205
- 158 Berger S. J. and Berger N. A. (1986) An enzymatic method for the measurement of nicotinamide mononucleotide pyrophosphorylase in cells and tissues. *Anal. Biochem.* **154**: 64–70
- 159 Berger S. J., Manory I., Sudar D. C., Krothapalli D. and Berger N. A. (1987) Pyridine nucleotide analog interference with metabolic processes in mitogen-stimulated human T lymphocytes. *Exp. Cell Res.* **173**: 379–387
- 160 Rocchigiani M., Micheli V., Duley J. A. and Simmonds H. A. (1992) Determination of nicotinamide phosphoribosyltransferase activity in human erythrocytes: high-performance liquid chromatography-linked method. *Anal. Biochem.* **205**: 334–336
- 161 Micheli V., Simmonds H. A., Sestini S. and Ricci C. (1990) Importance of nicotinamide as an NAD precursor in the human erythrocyte. *Arch. Biochem. Biophys.* **283**: 40–45
- 162 Micheli V., Sestini S., Rocchigiani M., Pescaglini M. and Ricci C. (1987) Nucleotide synthesis in human erythrocyte: correlations between purines and pyridines. *Biomed. Biochim. Acta.* **46**: S268–S272
- 163 Samal B., Sun Y., Stearns G., Xie C., Suggs S. and McNiece I. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. *Mol. Cell. Biol.* **14**: 1431–1437
- 164 Rongvaux A., Shea R. J., Mulks M. H., Gigot D., Urbain J., Leo O. et al. (2002) Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. *Eur. J. Immunol.* **32**: 3225–3234
- 165 Preiss J. and Handler P. (1958) Biosynthesis of diphosphopyridine nucleotide. *J. Biol. Chem.* **233**: 493–500
- 166 Nidel J. and Dietrich L. S. (1973) Nicotinate phosphoribosyltransferase of human erythrocytes. Purification and properties. *J. Biol. Chem.* **248**: 3500–3505
- 167 Vinitsky A. and Grubmeyer C. (1993) A new paradigm for biochemical energy coupling. *Salmonella typhimurium* nicotinate phosphoribosyltransferase. *J. Biol. Chem.* **268**: 26004–26010
- 168 Sestini S., Jacomelli G., Pescaglini M., Micheli V. and Pompucci G. (2000) Enzyme activities leading to NAD synthesis in human lymphocytes. *Arch. Biochem. Biophys.* **379**: 277–282
- 169 Schmidt-Brauns J., Herbert M., Kemmer G., Kraiss A., Schlör S. and Reidl J. (2001) Is a NAD pyrophosphatase activity necessary for *Haemophilus influenzae* type b multiplication in the blood stream? *Int. J. Med. Microbiol.* **291**: 219–225
- 170 Hillyard D., Rechsteiner M., Manlapaz-Ramos P., Imperial J. S., Cruz L. J. and Olivera B. M. (1981) The pyridine nucleotide cycle. Studies in *Escherichia coli* and the human cell line D98/AH2. *J. Biol. Chem.* **256**: 8491–8497
- 171 Sasiak K. and Saunders P. P. (1996) Purification and properties of a human nicotinamide ribonucleoside kinase. *Arch. Biochem. Biophys.* **333**: 414–418
- 172 Grossman L. and Kaplan N. O. (1958) Nicotinamide riboside phosphorylase from human erythrocytes. *J. Biol. Chem.* **231**: 717–726
- 173 White H. B. III (1981) Biosynthetic and salvage pathways of pyridine nucleotide coenzymes. In: *The Pyridine Nucleotide Coenzymes*, pp. 225–248, Everse J., Anderson B., You K. S. (eds), Academic Press, New York
- 174 Moat G. A. and Foster J. W. (1986) Biosynthesis and salvage pathways of pyridine nucleotides. In: *Pyridine Nucleotide Coenzymes*, Part B, pp. 1–24, Dolphin D., Poulson R., Avramovic O. (eds), Wiley-Interscience, New York
- 175 Yang J., Klaidman L. K., Nalbandian A., Oliver J., Chang M. L., Chan P. H. et al. (2002) The effects of nicotinamide on energy metabolism following transient focal cerebral ischemia in Wistar rats. *Neurosci. Lett.* **333**: 91–94